Supply shortage hits infant RSV antibody Beyfortus
Bio Pharma Dive
OCTOBER 25, 2023
The CDC is asking doctors to ration supply of Sanofi and AstraZeneca’s new RSV drug Beyfortus, as demand has outstripped supply.
UK doctors call for tighter rules on coronavirus antibody tests
pharmaphorum
AUGUST 21, 2020
Doctors have called for rules to be tightened on coronavirus antibody tests in the UK amid fears that false readings could put the public at risk. It’s not even known for sure that having antibodies against the SARS-CoV-2 coronavirus confers immunity. Feature image courtesy of Rocky Mountain Laboratories/NIH.
Doctors 
68
68 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Finding the North Star of therapeutic antibodies
Drug Discovery World
NOVEMBER 13, 2023
She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. This is a fully human monoclonal antibody (mAb) which selectively binds to the FcRn receptor with high-affinity and blocks it, thus leading to a decrease in IgG autoantibodies.
Antibody 59
59 
City of Hope Doctors Present New Research on Cancer Immunotherapies
BioTech 365
NOVEMBER 4, 2021
City of Hope Doctors Present New Research on Cancer Immunotherapies City of Hope Doctors Present New Research on Cancer Immunotherapies New data on bispecific antibodies and stem cell transplants will be presented in person and virtually at the American Society … Continue reading →
Doctors 40
40 
Regeneron tests COVID-19 antibody therapy in UK’s RECOVERY trial
pharmaphorum
SEPTEMBER 16, 2020
Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.
Antibody 98
98 
Unique antibody profile sets gluten sensitivity apart from celiac disease
Scienmag
AUGUST 31, 2020
NEW YORK, NY–A new study of the antibodies produced by people with gluten sensitivity may lead to a better way to detect the condition and treat it.
Antibody 60
60 
Coronavirus antibodies tests 'put public at risk'
The Pharma Data
AUGUST 20, 2020
Poor regulation of antibodies tests – that could indicate if someone has had coronavirus – could be putting the public at risk, doctors have warned. It is still not known whether having antibodies will protect people from a second infection. Coronavirus infection triggers the immune system to produce antibodies.
Antibody 52
52 
Turning science into business: An optimised alternative to antibodies
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. What advantages do they offer over antibodies?
Antibody 52
52 
As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused
STAT News
JULY 22, 2022
So Padgett was shocked last month when, during a Google search on new variants, she learned there was a drug available to protect patients like her daughter, a 23-year-old childhood cancer survivor whose immune system can’t make enough antibodies. Even more startling: It had been available since December.
Doctors 145
145 
No more needles for diagnostic tests?
Scienmag
JANUARY 22, 2021
Nearly pain-free microneedle patch can test for antibodies and more in the fluid between cells Credit: Image: Sisi Cao Blood draws are no fun. Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal […].
Antibody 61
61 
Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)
Rethinking Clinical Trials
JANUARY 17, 2024
The first monoclonal antibody (mABs) treatment for treatment of COVID-19 was approved in November 2020. UPMC built upon the success of the Remdesivir lottery and in December 2020, UPMC began infusing monoclonal antibodies across 45 UPMC locations. Only about 40% of our patients are enrolled in My UPMC.
Clinical Trials 169
169 
Should Your Child Get a COVID Test?
The Pharma Data
JANUARY 15, 2021
Molecular and antigen tests check for active infections, while antibody tests show whether a person has been infected in the past. Your child’s doctor can explain what each test does and when tests can be most useful. There are three main types of COVID-19 tests. © 2021 HealthDay.
Antibody 52
52 
Online health information: The game has changed
World of DTC Marketing
SEPTEMBER 14, 2021
Even if humoral immunity appears to wane, reductions in neutralizing antibody titre do not necessarily predict reductions in vaccine efficacy over time, and reductions in vaccine efficacy against mild disease do not necessarily predict reductions in the (typically higher) efficacy against severe disease.
Vaccination 159
159 
Roche on COVID-19 healthcare and testing: the pharmaphorum podcast
pharmaphorum
FEBRUARY 26, 2021
A former NHS doctor, he noted how stressful and draining some days can be when working at healthcare’s frontline – even in normal times, and that the current fight against the pandemic brings little respite to staff.
Doctors 71
71 
EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout
pharmaphorum
JUNE 13, 2022
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory Hodgkin lymphoma at the EHA annual meeting. “These results offer hope to patients and doctors who need a new option.”
Drugs 98
98 
Do pharma marketers have a responsibility to the public?
World of DTC Marketing
MARCH 16, 2021
Do I have a responsibility to share — on every occasion, random and formal, to family, friends, and strangers alike — my knowledge on the vaccines, monoclonal antibodies, the latest news from the Lancet or JAMA, why RNA is not voodoo, how Phase 4 safety trials are happening as I write…The answer is simple: yes.
Marketing 180
180 
Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
The Pharma Data
NOVEMBER 4, 2020
If your doctor decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible. Your doctor will decide if you need additional vaccination. Your doctor will give you a Patient Safety Card about the risk of meningococcal infection.
Doctors 52
52 
Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod
XTalks
JUNE 30, 2023
Severe hemophilia A is usually treated with FVIII replacement therapy or an antibody-based drug to improve the ability of blood to clot and reduce the likelihood of bleeding. To be eligible for the therapy, patients must test negative for AAV5-targeted antibodies.
Gene Therapy 98
98 
A Horizon of hope: UPLIZNA data, NMOSD, and ECTRIMS
pharmaphorum
JANUARY 15, 2023
Yet, according to NMO UK , others might also have antibodies recognised as being associated with this disorder, such as Aquaporin 4 (AQP4) and Myelin Oligodendrocyte Glycoprotein (MOG). However, each person with NMOSD will experience different symptoms, and each will require individually tailored care and support. Patterson explained.
Antibody 105
105 
Coronavirus: Exposure rate 'similar' in London and Stockholm
The Pharma Data
AUGUST 11, 2020
Exposure to Covid-19 is similar in Stockholm and London, based on antibody tests, despite different lockdown strategies, research suggests. Health experts predicted that 40% of the population in the capital, Stockholm, would have developed antibodies to the disease by May. The actual figure was 17%, according to a review of evidence.
Antibody 52
52 
Advancements in upstream CLD for enhanced biotherapeutics production
Drug Discovery World
NOVEMBER 27, 2023
As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.
Production 59
59 
WHO Calls on Roche and Regeneron to Lower Costs for Life-Saving COVID-19 Treatment
XTalks
JULY 8, 2021
The drugs are monoclonal antibodies against the IL-6 receptor. Monoclonal antibodies generally do not come cheap. Despite the recent authorizations and recommendations, many doctors had already been using these drugs as a last resort for severely ill COVID-19 patients, according to Fierce Pharma. We must urgently change this.”.
Doctors 98
98 
Novartis’ Aimovig tops topiramate in migraine face-off
pharmaphorum
NOVEMBER 4, 2020
Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial.
Botox 95
95 
Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis
Delveinsight
OCTOBER 1, 2021
This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. This medication is administered by injection under the skin or slowly into a vein as directed by the doctor.
Marketing 85
85 
The Pharma Data - Untitled Article
The Pharma Data
APRIL 29, 2022
The vaccine candidate demonstrated superior neutralizing antibody titres over AstraZeneca’s Vaxzevria™ (control vaccine), a currently authorized COVID-19 vaccine. The results of the Phase III clinical trial show a superior neutralizing antibody response of SKYCovione™ against SARS-CoV-2 parental strain, 2.93
Vaccination 52
52 
Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech
pharmaphorum
JANUARY 7, 2021
Used with widely available PET scan technology, ImaginAb’s technology allows doctors to track the T-cell immune response to cancer in real time and it has already picked up a multi-party deal involving Pfizer, AstraZeneca and Takeda.
Doctors 53
53 
Sickle Cell Disease: The Importance of Amplifying Patient Voices
Advarra
MARCH 10, 2023
A visit to a podiatrist and family doctor yielded less than satisfactory diagnoses. One surgery later, Moss spoke with a second doctor who immediately identified it as a sickle cell ulcer, and it would’ve gone away on its own. Moss has had many instances where she had to educate her health care providers on her disease.
Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response
pharmaphorum
SEPTEMBER 7, 2020
Preliminary results published in The Lancet are from a non-randomised phase 1/2 trial of 76 people aged 18-60, which found an antibody response within 21 days and no serious adverse events after 42 days. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.
Immune Response 106
106 
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
The Pharma Data
AUGUST 16, 2020
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks. First and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology.
FDA Approval 52
52 
AbbVie spies potential in Regenxbio eye disease gene therapy
pharmaphorum
SEPTEMBER 13, 2021
The partnership centres on RGX314, which delivers a gene coding for an antibody against VEGF – a well-established approach to treating wet AMD and the target of current blockbuster drugs like Bayer’s Eylea (aflibercept) and Novartis/Roche’s Lucentis (ranibizumab). AbbVie – which is also putting up $1.38
Gene Therapy 97
97 
WHO Calls on Roche and Sanofi to Lower Costs for Life-Saving COVID-19 Treatment
XTalks
JULY 8, 2021
The drugs are monoclonal antibodies against the IL-6 receptor. Monoclonal antibodies generally do not come cheap. Despite the recent authorizations and recommendations, many doctors had already been using these drugs as a last resort for severely ill COVID-19 patients, according to Fierce Pharma. We must urgently change this.”.
Doctors 52
52 
Leqembi (lecanemab) Granted Accelerated Approval by the FDA as Alzheimer’s Disease Treatment
XTalks
JANUARY 12, 2023
Patients at an early stage of the disease and their caregivers can now consider a new treatment option with their doctors. Leqembi is a humanized immunoglobulin gamma 1 (lgG1) monoclonal antibody that targets both soluble and insoluble forms of aggregated amyloid-beta plaques. What We Know About Leqembi and Clinical Trial Results.
2021 Young Scientist Award winners announced
The Pharma Data
JUNE 30, 2021
For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award.
Scientist 52
52 
NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta
pharmaphorum
APRIL 20, 2021
The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried.
Sales 111
111 
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
The Pharma Data
JANUARY 17, 2021
. The treatment is based on the Grifols immunoglobulin Gamunex®-C, and contains anti-SARS-COV-2 polyclonal antibodies from plasma donors who have recovered from COVID-19. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P, BARCELONA, Spain , Jan.
Study tracks COVID-19 antibodies over time
The Pharma Data
APRIL 18, 2022
The antibodies generated by Pfizer’s COVID-19 vaccine rise more slowly and decline more quickly than those generated by the Moderna vaccine, according to a new study from UVA Health. The researchers determined that both vaccines generated similar peak levels of COVID-fighting antibodies. ” Tracking the COVID-19 Vaccines.
Antibody 52
52 
Moderna and BioNTech – who are they?
pharmaphorum
DECEMBER 21, 2020
The body produces antibodies against the protein, which neutralise the virus in the event of an infection. Moderna’s founders were led by Derrick Rossi, a post doctorate fellow from Stanford University who championed the technology to a team from Flagship Ventures, a Massachusetts firm founded and run by Noubar Afeyan.
Vaccination 103
103 
AZ CEO Soriot urges caution on COVID booster doses
pharmaphorum
SEPTEMBER 8, 2021
. “Because NHS staff and resources are scarce, another national mobilisation would potentially leave us with fewer resources for cancer screenings and the other care provided by doctors and nurses each day,” says the AZ executives. ” The post AZ CEO Soriot urges caution on COVID booster doses appeared first on.
Vaccination 75
75 
Roche claims EU okay for Herceptin/Perjeta combination Phesgo
pharmaphorum
DECEMBER 23, 2020
Phesgo combines the anti-HER2 antibodies in Herceptin (trastuzumab) and Perjeta (pertuzumab) in a subcutaneous injection that takes a few minutes to deliver.
Sales 52
52 
NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo
pharmaphorum
NOVEMBER 12, 2021
Until now however, NHS doctors could only access it through a compassionate use scheme. Poteligeo is a humanised monoclonal antibody, which acts against the against CC chemokine receptor 4 (CCR4) that is often found in the blood cancer cells including CTCL.
Drugs 52
52 
Roche eyes October decision by FDA for wet AMD implant
pharmaphorum
JUNE 24, 2021
Roche bought ex-US rights to the PDS version from Novartis in 2019, giving it total control of the implant product, while Novartis has focused on the development of longer-acting VEGF antibody Beovu (brolucizumab), which is dosed every two or three months. The post Roche eyes October decision by FDA for wet AMD implant appeared first on.
Sales 89
89 
Inhale, Exhale: Living with Severe Asthma and Severe Eosinophilic Asthma
pharmaphorum
SEPTEMBER 16, 2020
Patients with SEA can be put on a biologic drug to reduce inflammation in the airways, and there are a number of monoclonal antibody drugs available or in development. In SEA, there are higher numbers of eosinophils in the blood, lung tissue and mucus, meaning the whole respiratory tract suffers from airflow obstruction. Impact on daily life.
Doctors 105
105 
Let's personalize your content